Skip to main content

Eraxis Side Effects

Generic name: anidulafungin

Medically reviewed by Drugs.com. Last updated on Dec 22, 2023.

Note: This document contains side effect information about anidulafungin. Some dosage forms listed on this page may not apply to the brand name Eraxis.

Applies to anidulafungin: intravenous powder for solution.

Serious side effects of Eraxis

Along with its needed effects, anidulafungin (the active ingredient contained in Eraxis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking anidulafungin:

Less common

Rare

Other side effects of Eraxis

Some side effects of anidulafungin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Rare

For Healthcare Professionals

Applies to anidulafungin: intravenous powder for injection.

General

The most common side effects reported during studies in patients with candidemia and other Candida infections were hypokalemia, nausea, diarrhea, vomiting, pyrexia, and insomnia. This drug was discontinued in 11.5% of patients due to side effects; the most common side effects leading to discontinuation were multi-organ failure and systemic Candida infection.

The most common side effects reported during a study in patients with esophageal candidiasis were diarrhea, pyrexia, anemia, headache, vomiting, nausea, and dyspepsia. This drug was discontinued in 9% of patients due to side effects; the most common side effect leading to discontinuation was maculopapular rash.[Ref]

Metabolic

Very common (10% or more): Hypokalemia (up to 25%), hypomagnesemia (up to 12%)

Common (1% to 10%): Hypoglycemia, hyperglycemia, hyperkalemia, dehydration

Uncommon (0.1% to 1%): Hyperuricemia, hypocalcemia, hyponatremia, hypoalbuminemia, hypophosphatemia

Frequency not reported: Hypercalcemia, hypernatremia, hypoproteinemia[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 24%), diarrhea (up to 18%), vomiting (up to 18%)

Common (1% to 10%): Constipation, dyspepsia, abdominal pain, oral candidiasis

Uncommon (0.1% to 1%): Upper abdominal pain, dry mouth, esophageal ulcer

Frequency not reported: Increased amylase, increased lipase, fecal incontinence, gastroesophageal reflux disease, abdominal distension, stomatitis, gastroenteritis[Ref]

Other

Very common (10% or more): Pyrexia (up to 18%), bacteremia (up to 18%), increased blood alkaline phosphatase (up to 12%), peripheral edema (up to 11%)

Common (1% to 10%): Sepsis, chest pain, flushing

Uncommon (0.1% to 1%): Hot flushes, chills, increased blood LDH

Frequency not reported: Infusion-related reaction, rigors, clostridial infection, fungemia, candidiasis, multi-organ failure, systemic Candida infection, infusion-related side effects (possibly histamine-mediated; included rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, hypotension), decreased potassium, decreased magnesium, device-related infection[Ref]

Cardiovascular

Very common (10% or more): Hypotension (up to 15%), hypertension (up to 12%), deep vein thrombosis (up to 10%)

Common (1% to 10%): ECG QT prolonged

Uncommon (0.1% to 1%): Phlebitis, superficial thrombophlebitis

Frequency not reported: ECG early transition, atrial fibrillation, bundle branch block (right), sinus arrhythmia, ventricular extrasystoles[Ref]

Psychiatric

Very common (10% or more): Insomnia (up to 15%)

Common (1% to 10%): Confusional state, depression

Uncommon (0.1% to 1%): Anxiety, delirium, auditory hallucination

Frequency not reported: Agitation[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (up to 15%)

Uncommon (0.1% to 1%): Hematuria[Ref]

Respiratory

Very common (10% or more): Dyspnea (up to 12%), pleural effusion (up to 10%)

Common (1% to 10%): Cough, pneumonia, respiratory distress

Frequency not reported: Epistaxis, lower respiratory tract infection, upper respiratory tract infection, hemoptysis

Postmarketing reports: Bronchospasm[Ref]

Hematologic

Common (1% to 10%): Anemia, increased WBC, thrombocythemia, leukocytosis, coagulopathy, thrombocytopenia, decreased platelet count

Uncommon (0.1% to 1%): Neutropenia, leukopenia, lymphangitis, decreased lymphocyte count

Frequency not reported: Prothrombin time prolonged, increased platelet count, pancytopenia, thrombocytosis, febrile neutropenia[Ref]

Nervous system

Common (1% to 10%): Headache, convulsion

Uncommon (0.1% to 1%): Dizziness, paresthesia, central pontine myelinolysis, dysgeusia, Guillain-Barre syndrome, tremor, unilateral deafness

Frequency not reported: Seizure[Ref]

Hepatic

Common (1% to 10%): Increased hepatic enzymes, increased ALT, increased AST, increased blood bilirubin, cholestasis, increased GGT

Uncommon (0.1% to 1%): Hepatic necrosis

Frequency not reported: Significant hepatic dysfunction, abnormal liver function tests, hepatitis, hepatic failure, increased transaminases[Ref]

Hypersensitivity

Postmarketing reports: Anaphylactic shock, anaphylactic reaction[Ref]

Dermatologic

Common (1% to 10%): Decubitus ulcer, rash, pruritus

Uncommon (0.1% to 1%): Urticaria, angioneurotic edema, hyperhidrosis

Frequency not reported: Maculopapular rash, erythema, increased sweating, generalized rash[Ref]

Renal

Common (1% to 10%): Increased blood creatinine

Uncommon (0.1% to 1%): Renal failure

Frequency not reported: Increased urea[Ref]

Musculoskeletal

Common (1% to 10%): Back pain

Uncommon (0.1% to 1%): Myalgia, monoarthritis, increased blood creatine phosphokinase

Frequency not reported: Pain in extremity[Ref]

Local

Uncommon (0.1% to 1%): Infusion site pain, injection site reaction[Ref]

Ocular

Uncommon (0.1% to 1%): Altered visual depth perception

Frequency not reported: Eye pain, blurred vision, visual disturbance, periorbital edema[Ref]

References

1. Product Information. Eraxis (anidulafungin). Pfizer U.S. Pharmaceuticals Group. 2006.

2. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-4.

3. Cerner Multum, Inc. UK Summary of Product Characteristics.

4. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215-22.

5. Anidulafungin (Eraxis) for Candida infections. Med Lett Drugs Ther. 2006;48:43-4.

6. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47:461-70.

7. Cerner Multum, Inc. Australian Product Information.

8. Thompson GR 3rd, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med. 2009;30:203-15, v.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.